For example, in a study of pancreatic malignancy, it was shown that the CCR2 inhibitor PF-04136309 combined with FOLFIRINOX chemotherapy could achieve an objective tumor response and was safe and well tolerated (101). This evidence concerns the gene CCR2 and neoplasm.